Document Detail

Effects of etanercept on urine neopterin levels in patients with psoriasis in a controlled, open-label study.
MedLine Citation:
PMID:  19348656     Owner:  NLM     Status:  MEDLINE    
Neopterin is an immunological marker of cellular immune activation. Etanercept is a tumor necrosis factor-alpha (TNF-alpha) antagonist that decreases excessive levels of TNF-alpha associated with inflammatory disease down to physiological levels. The objective of this study was to investigate urine neopterin levels in psoriatic patients treated with etanercept, to study the effect of etanercept as a TNF-alpha blocker on urine neopterin levels. Urine neopterin levels and urine neopterin/creatinine ratios were measured by high-performance liquid chromatography in 22 patients with psoriasis before and after treatment with etanercept. Results were compared with a group of 20 healthy volunteers, and 20 patients with inflammatory skin diseases as control groups. Urine neopterin levels, neopterin/creatinine ratios and Psoriasis Area and Severity Index (PASI) scores were evaluated at baseline, and the 12th and 24th week after treatment. Urine neopterin levels were significantly elevated in the psoriatic group compared with control and inflammatory skin diseases groups (P < 0.05). Urine neopterin levels were significantly reduced after etanercept treatment. Statistically we did not find any correlation between neopterin levels and PASI scores. Our findings indicate that urine neopterin concentrations may reflect the disease activity in psoriasis, and may be used as a marker for monitoring disease activity and response to treatment with etanercept in psoriatic patients.
Erol Koc; Mustafa Tunca; Emin Ozgur Akgul; Ahmet Akar; Yasemin Kurt; Zafer Kurumlu; Kemal Erbil; Selim Kilic
Related Documents :
22633156 - Impaired saccadic adaptation in schizophrenic patients with high neurological soft sign...
20948096 - Comparison of topical tretinoin and betamethasone in oral lichen planus.
21957686 - Eeg use in a tertiary referral centre.
22100146 - Dynamics of frequency flow in epileptic brain during extra-temporal partial and idiopat...
12791156 - Analysis of kinesiograph recordings and masticatory efficiency after treatment of non-r...
7993156 - Enhanced susceptibility to amiodarone-induced hypothyroidism in patients with thyroid a...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  The Journal of dermatology     Volume:  36     ISSN:  1346-8138     ISO Abbreviation:  J. Dermatol.     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-04-07     Completed Date:  2009-07-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7600545     Medline TA:  J Dermatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  191-6     Citation Subset:  IM    
Deparmtent of Dermatology, Gulhane School of Medicine, Ankara, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Markers / urine
Creatinine / urine
Dermatitis / drug therapy,  immunology,  urine
Immunity, Cellular
Immunoglobulin G / therapeutic use*
Middle Aged
Neopterin / urine*
Psoriasis / drug therapy*,  immunology,  urine*
Receptors, Tumor Necrosis Factor / therapeutic use*
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Young Adult
Reg. No./Substance:
0/Biological Markers; 0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 0/Tumor Necrosis Factor-alpha; 185243-69-0/TNFR-Fc fusion protein; 60-27-5/Creatinine; 670-65-5/Neopterin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Severity scores, itch scores and plasma substance P levels in atopic dermatitis treated with standar...
Next Document:  Clinical usefulness of a supplementary cyclosporin administration with a topical application of maxa...